

19. The polynucleotide of claim 16 comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.

20. The polynucleotide of claim 16, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8.

21. The polynucleotide of claim 16, wherein the polypeptide is a myo-inositol-1 (or 4)-monophosphatase.

22. An isolated polypeptide, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8 have at least 80% identity based on the Clustal alignment method.

23. The polypeptide of Claim 22, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8 have at least 90% identity based on the Clustal alignment method.

24. The polypeptide of Claim 22, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8 have at least 95% identity based on the Clustal alignment method.

25. The polypeptide of claim 22, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8.

26. The polypeptide of claim 22, wherein the polypeptide is a myo-inositol-1 (or 4)-monophosphatase.

27. A chimeric gene comprising the polynucleotide of claim 26 operably linked to a regulatory sequence.

28. A vector comprising the polynucleotide of claim 26.

29. A method for transforming a cell comprising transforming a cell with the polynucleotide of claim 26.

30. The cell produced by the method of claim 29.

31. An isolated polynucleotide comprising a nucleotide sequence comprised by the polynucleotide of claim 26, wherein the nucleotide sequence contains at least 30 nucleotides.

32. An isolated polynucleotide comprising:

(a) a nucleotide sequence encoding a polypeptide, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20 have at least 80% identity based on the Clustal alignment method, or

(b) the complement of the nucleotide sequence.

33. The polynucleotide of Claim 32, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20 have at least 90% identity based on the Clustal alignment method.

34. The polynucleotide of Claim 32, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20 have at least 95% identity based on the Clustal alignment method.

35. The polynucleotide of claim 32 comprising the nucleotide sequence of SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:19.

36. The polynucleotide of claim 32, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20.

37. The polynucleotide of claim 32, wherein the polypeptide is a myo-inositol-1 (or 4)-monophosphatase.

38. An isolated polypeptide, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20 have at least 80% identity based on the Clustal alignment method.

39. The polypeptide of Claim 38, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20 have at least 90% identity based on the Clustal alignment method.

40. The polypeptide of Claim 38, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20 have at least 95% identity based on the Clustal alignment method.

41. The polypeptide of claim 38, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20.

42. The polypeptide of claim 38, wherein the polypeptide is a myo-inositol-1 (or 4)-monophosphatase.

43. A chimeric gene comprising the polynucleotide of claim 32 operably linked to a regulatory sequence.

44. A vector comprising the polynucleotide of claim 32.

45. A method for transforming a cell comprising transforming a cell with the polynucleotide of claim 32.

46. The cell produced by the method of claim 45.

47. An isolated polynucleotide comprising a nucleotide sequence comprised by the polynucleotide of claim 32, wherein the nucleotide sequence contains at least 30 nucleotides.